76 related articles for article (PubMed ID: 24224747)
1. Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin.
Striki A; Manolakopoulos S; Deutsch M; Mela M; Kalafateli M; Schini M; Anagnostou O; Triantos C; Andreadis I; Ketikoglou I; Papatheodoridis G; Pectasides D
J Viral Hepat; 2014; 21(9):624-32. PubMed ID: 24224747
[TBL] [Abstract][Full Text] [Related]
2. The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C.
Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1192-9. PubMed ID: 21971375
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
Roomer R; Hansen BE; Janssen HL; de Knegt RJ
Hepatology; 2010 Oct; 52(4):1225-31. PubMed ID: 20830784
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia.
Iacobellis A; Cozzolongo R; Minerva N; Valvano MR; Niro GA; Fontana R; Palmieri O; Ippolito A; Andriulli A
Dig Liver Dis; 2014 Jul; 46(7):621-4. PubMed ID: 24675038
[TBL] [Abstract][Full Text] [Related]
5. Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection.
Juarez-Navarro A; Vera-de-León L; Navarro JM; Chirino-Sprung R; Díaz-Hernandez M; Casillas-Davila L; Dehesa-Violante M
Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):317-22. PubMed ID: 16082419
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C.
Li Z; Zhang Y; An J; Feng Y; Deng H; Xiao S; Ji F
J Clin Virol; 2014 Jul; 60(3):190-5. PubMed ID: 24830933
[TBL] [Abstract][Full Text] [Related]
7. Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice.
Yang JF; Hsieh MY; Hou NJ; Dai CY; Huang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chuang WL; Yu ML
Aliment Pharmacol Ther; 2009 May; 29(9):1000-10. PubMed ID: 19210290
[TBL] [Abstract][Full Text] [Related]
8. Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis.
Maan R; van der Meer AJ; Hansen BE; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Manns MP; Zeuzem S; Janssen HL; de Knegt RJ; Veldt BJ
J Gastroenterol Hepatol; 2015 Jun; 30(6):1057-64. PubMed ID: 25682797
[TBL] [Abstract][Full Text] [Related]
9. [A study of the relationship between neutropenia and clinical infection risk during treatment with peginterferon alfa-2a and ribavirin for chronic hepatitis C].
Sun LJ; Yu JW; Kang P; Zhao YH; Yan BZ
Zhonghua Nei Ke Za Zhi; 2012 Jan; 51(1):46-50. PubMed ID: 22490760
[TBL] [Abstract][Full Text] [Related]
10. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation?
Puoti M; Babudieri S; Rezza G; Viale P; Antonini MG; Maida I; Rossi S; Zanini B; Putzolu V; Fenu L; Baiguera C; Sassu S; Carosi G; Mura MS
Antivir Ther; 2004 Aug; 9(4):627-30. PubMed ID: 15456094
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.
Giannini EG; Marenco S; Fazio V; Pieri G; Savarino V; Picciotto A
Liver Int; 2012 Aug; 32(7):1113-9. PubMed ID: 22471814
[TBL] [Abstract][Full Text] [Related]
12. Neutropenia during therapy with peginterferon and ribavirin in HIV-infected subjects with chronic hepatitis C and the risk of infections.
Serrano-Villar S; Quereda C; Moreno A; Pérez-Elías MJ; Casado JL; Royuela A; Dronda F; Navas E; Hermida JM; Moreno S
Clin Infect Dis; 2013 Aug; 57(3):458-64. PubMed ID: 23575196
[TBL] [Abstract][Full Text] [Related]
13. Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis.
Giorgini A; Capsoni F; Podda M; Lleó A; Battezzati PM; Ongari AM; Selmi C; Benetti A; Malinverno F; Rossaro L; Gershwin ME; Zuin M
Ann N Y Acad Sci; 2009 Sep; 1173():847-57. PubMed ID: 19758237
[TBL] [Abstract][Full Text] [Related]
14. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.
Soza A; Everhart JE; Ghany MG; Doo E; Heller T; Promrat K; Park Y; Liang TJ; Hoofnagle JH
Hepatology; 2002 Nov; 36(5):1273-9. PubMed ID: 12395340
[TBL] [Abstract][Full Text] [Related]
15. Low weight predicts neutropenia and peginterferon alfa-2a dose reductions during treatment for chronic hepatitis C.
Rotman Y; Katz L; Cohen M; Cohen-Ezra O; Manhaim V; Braun M; Ben-Ari Z; Tur-Kaspa R
J Viral Hepat; 2009 May; 16(5):340-5. PubMed ID: 19220735
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow suppression or active proliferation? An analysis of neutropenia after pegylated interferon treatment of patients with chronic hepatitis C.
Liu YL; Du XF; Chen XY; Ma LN; Guo DD; Lu JF; Cao ZH; Zhang YH
Scand J Infect Dis; 2013 Dec; 45(12):939-43. PubMed ID: 24090457
[TBL] [Abstract][Full Text] [Related]
17. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.
Nachnani JS; Rao GA; Bulchandani D; Pandya PK; Alba LM
Ann Hematol; 2010 Feb; 89(2):121-5. PubMed ID: 19565241
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin.
Fouad YM; Khalaf H; Ibraheem H; Rady H; Helmy AK
Int J Infect Dis; 2012 Jan; 16(1):e67-71. PubMed ID: 22115957
[TBL] [Abstract][Full Text] [Related]
19. Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease.
Maasoumy B; Port K; Deterding K; Höner Zu Siederdissen C; Markova AA; Rogalska-Taranta M; Manns MP; Wedemeyer H; Cornberg M
Eur J Gastroenterol Hepatol; 2014 Aug; 26(8):836-45. PubMed ID: 24987822
[TBL] [Abstract][Full Text] [Related]
20. The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis.
Londoño MC; Perelló C; Cabezas J; Cañete N; Lens S; Mariño Z; Gambato M; Rodríguez R; Menéndez S; Carrión JA; Crespo J; Calleja JL; Forns X
J Hepatol; 2015 Feb; 62(2):311-6. PubMed ID: 25281861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
